These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 28008585

  • 1. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
    Li XN, Bu HM, Ma XH, Lu S, Zhao S, Cui YL, Sun J.
    Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
    [Abstract] [Full Text] [Related]

  • 2. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
    Eftekhari S, Montazeri H, Tarighi P.
    Eur J Pharmacol; 2020 Jul 05; 878():173102. PubMed ID: 32283060
    [Abstract] [Full Text] [Related]

  • 3. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.
    Breast Cancer Res Treat; 2012 Apr 05; 132(2):449-61. PubMed ID: 21638053
    [Abstract] [Full Text] [Related]

  • 4. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
    Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH.
    J Neurochem; 2010 Jun 05; 113(6):1621-31. PubMed ID: 20374430
    [Abstract] [Full Text] [Related]

  • 5. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
    Ligumsky H, Amir S, Arbel Rubinstein T, Guion K, Scherf T, Karasik A, Wolf I, Rubinek T.
    Med Oncol; 2024 May 06; 41(6):138. PubMed ID: 38705935
    [Abstract] [Full Text] [Related]

  • 6. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
    Koehler JA, Kain T, Drucker DJ.
    Endocrinology; 2011 Sep 06; 152(9):3362-72. PubMed ID: 21771884
    [Abstract] [Full Text] [Related]

  • 7. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
    Zhao H, Wei R, Wang L, Tian Q, Tao M, Ke J, Liu Y, Hou W, Zhang L, Yang J, Hong T.
    Am J Physiol Endocrinol Metab; 2014 Jun 15; 306(12):E1431-41. PubMed ID: 24801389
    [Abstract] [Full Text] [Related]

  • 8. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 9. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
    Shi L, Ji Y, Jiang X, Zhou L, Xu Y, Li Y, Jiang W, Meng P, Liu X.
    Cardiovasc Diabetol; 2015 Feb 07; 14():18. PubMed ID: 25855361
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
    Wu X, Li S, Xue P, Li Y.
    Exp Cell Res; 2017 Nov 15; 360(2):281-291. PubMed ID: 28919123
    [Abstract] [Full Text] [Related]

  • 11. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
    Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T.
    Diabetes; 2014 Nov 15; 63(11):3891-905. PubMed ID: 24879833
    [Abstract] [Full Text] [Related]

  • 12. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
    Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, Greig NH.
    J Neurochem; 2015 Dec 15; 135(6):1203-1217. PubMed ID: 25982185
    [Abstract] [Full Text] [Related]

  • 13. Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway.
    Zhang X, Bi L, Ye Y, Chen J.
    Nutr Cancer; 2014 Dec 15; 66(4):656-61. PubMed ID: 24666255
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
    Mhaidat NM, Zhang XD, Jiang CC, Hersey P.
    Clin Cancer Res; 2007 Feb 15; 13(4):1308-14. PubMed ID: 17317842
    [Abstract] [Full Text] [Related]

  • 15. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
    Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, Shu H, Liu Y, Li CL.
    Peptides; 2013 Jan 15; 39():71-9. PubMed ID: 23116613
    [Abstract] [Full Text] [Related]

  • 16. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
    Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J, Liu Y, Yang J, Hong T.
    Diabetes Obes Metab; 2014 Sep 15; 16(9):850-60. PubMed ID: 24641303
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.
    Sharma MK, Jalewa J, Hölscher C.
    J Neurochem; 2014 Feb 15; 128(3):459-71. PubMed ID: 24112036
    [Abstract] [Full Text] [Related]

  • 18. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation.
    Ye Y, Hou R, Chen J, Mo L, Zhang J, Huang Y, Mo Z.
    Horm Metab Res; 2012 Apr 15; 44(4):263-7. PubMed ID: 22328166
    [Abstract] [Full Text] [Related]

  • 19. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.
    Andreozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, Beguinot F, Sesti G, Miele C, Folli F.
    J Transl Med; 2016 Jul 30; 14(1):229. PubMed ID: 27473212
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats.
    Fontana J, Kučera O, Mezera V, Anděl M, Červinková Z.
    Physiol Res; 2017 Nov 24; 66(5):833-844. PubMed ID: 28730824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.